The marine environment is a rich source for unique actinomycete bacteria of significant biological and chemical diversity. 1, 2 Marineobligate and marine-derived actinomycetes have been shown to be the source of structurally diverse secondary metabolites, many of which have been shown to possess interesting anticancer properties. 3 The discovery of antibiotics from this source is far less developed, but promising antibiotics such as anthracimycin provide significant motivation to explore this source further. 4 Earlier, we showed that the marine-derived Streptomyces sp., strain CNB-091, produces a suite of at least five structurally unprecedented depsipeptides, salinamides A − E, that show significant antibacterial and anti-inflammatory properties. 5, 6 Subsequently, salinamide A was shown to possess significant inhibitory activity against RNA polymerase (RNAP) from Gram-positive and Gram-negative bacteria. 7, 8 As part of a collaborative program to further explore the chemical biology of the RNAP-inhibitory activity of the salinamides, we examined in more detail the extract and semi-purified fractions from the recultivation of Streptomyces sp. CNB-091 and report here the isolation of a new salinamide analog, salinamide F, which, like salinamide A, also possesses significant RNAP-inhibitory and antibacterial activity.
Isolation and purification of salinamide F
The ethyl acetate extract (3.5 g), from cultivated strain CNB091, was subjected to silica vacuum flash chromatography using sequential mixtures of dichloromethane and methanol as eluents (elution order: 1, 2, 3, 4, 5, 10, 15, 20 and 30% methanol in dichloromethane, and 100% methanol). Guided by the results of bioassays and 1 H NMR analyses, the fractions containing bioactive metabolites were combined (210.0 mg) and purified using a C 8 reversed-phase semi-preparative HPLC column (YMC ODS-A column, 1 × 25 cm, 50% aqueous MeCN) to yield 13.2 mg of salinamide F (1) as pale yellow amorphous solid along with the previously described salinamides A and B and minor amounts of salinamides C-E.
Preparation of the acetonide 4
Salinamide F (1, 2 mg) was dissolved in dry acetone (1 ml), and BF 3 ·Et 2 O (20 μl) was added at 0°C. The reaction was allowed to stir for 3 h at 0°C, and then quenched with saturated aqueous NaHCO 3 . Next, the aqueous phase was extracted twice with ethyl acetate. The combined ethyl acetate solutions were concentrated under reduced pressure, and the residue was purified by C 8 reversed-phase semi-preparative HPLC (YMC ODS-A column, 1 × 25 cm, 50% aqueous acetonitrile) to yield 1.4 mg of the acetonide 4 as pale yellow solid.
− 72 to +367; prepared by PCR from plasmid pARTaqN25-340-tR2 11 ), 100 μM ATP, 100 μM GTP, 100 μM UTP and 100 μM CTP in transcription buffer (50 mM Tris-HCl, pH 8.0, 100 mM KCl, 10 mM MgCl 2 , 1 mM DTT, 10 μg ml − 1 bovine serum albumin, 5% methanol and 5.5% glycerol). Components other than DNA and NTPs were pre-incubated for 10 min at 37°C. Reactions were carried out by addition of DNA and incubation for 15 min at 37°C, followed by addition of NTPs and incubation for 60 min at 37°C. DNA was removed by addition of 1 μl 5mM CaCl 2 and 2 U DNase I (Ambion), followed by incubation for 90 min at 37°C. RNA was quantified by addition of 100 μl Quant-iT RiboGreen RNA Reagent (Life Technologies, Carlsbad, CA, USA; 1:500 dilution in 10 mM Tris-HCl, pH 8.0, 1 mM EDTA), followed by incubation for 10 min at 22°C, and measurement of fluorescence intensity (excitation wavelength = 485 nm and emission wavelength = 535 nm; GENios Pro microplate reader (Tecan, Männedorf, Switzerland)).
Antibacterial activity
Minimum inhibitory concentrations (MICs) were quantified using broth microdilution assays; 12 using a starting cell density of 2 × 10 5 c.f.u. ml − 1 , LB broth 13 and an air atmosphere for E. D21f2tolC (tolC:Tn10 rfa lac28 proA23 trp30 his51 rpsL173 ampC tsx81; strain with cell-envelope defects resulting in increased susceptibility to hydrophobic agents, including salinamides 8, 14 ), S. aureus (ATCC 12600), Enterococcus faecalis (ATCC 19433) and Enterobacter cloacae (ATCC 13047); and using a starting cell density of 2 × 10 5 c.f.u. ml − 1 , Haemophilus Test Medium broth, 15 and a 7% CO 2 , 6% O 2 , 4% H 2 , 83% N 2 atmosphere for Haemophilus influenzae (ATCC 49247) and Neisseria gonorrhoeae (ATCC 19424).
Salinamide F (1), a new bicyclic depsipeptide, was isolated in addition to the known salinamides A (3) and B (2) (Figure 1 ), as well as salinamides C-E, which were produced in minor amounts but not purified. (Figure 2 ) supporting this suggestion. The remaining 1 H and 13 C NMR signals for 1 were virtually identical to those of salinamide A (3). 5, 6 The relative configuration at C40 was assigned by analysis of 2D ROESY NMR data derived from 1 and its acetonide derivative 4 ( Figure 3 ). For salinamide F (1), NOE correlations between H 2 -40 (δ H 3.47, m), H-6 (δ H 6.19, d, J = 15.0) and H-8 (δ H 4.61, m) also suggested the opening of the epoxide ring (C-7-O-41-C-40) with retention of configuration at the quaternary center. To confirm this, the acetonide derivative 4 was prepared and its relative configuration evaluated by ROESY NMR experiments using methods alrerady applied in similar systems. 16 Salinamide F showed potent inhibition of Gram-positive and Gram-negative bacterial RNAP, with IC50 = 4 μM for S. aureus RNAP and 2 μM for E. coli RNAP. Salinamide F exhibited significant antibacterial activity against Grampositive and Gram-negative bacteria, showing MIC 50 = 12.5 μg ml − 1 for Enterococcus faecalis, 100 μg ml − 1 for S. aureus, 12.5 μg ml − 1 for H. influenzae, 25 μg ml − 1 for Neisseria gonorrhoeae, 50 μg ml − 1 for Enterobacter cloacae and 0.20 μg ml − 1 for E. coli D21f2tolC. The comparable RNAP-inhibitory activities of salinamide F (1) and salinamides A (3) and B (2) 
Abbreviations: MIC, minimum inhibitory concentration; RNAP, RNA polymerase.
corresponding clorohydrin functionality in salinamide B are not essential for RNAP inhibition. 8 Substitutions of the RNAP β and β' subunits that confer high-level (X8-fold) resistance to salinamides A (3) and (2) 8 also confer high-level resistance to salinamide F (1) ( Table 2 ). We infer that salinamide F inhibits RNAP through the same binding site on RNAP as salinamides A and B (i.e., the 'Sal target,' comprising residues of the 'F-loop' and 'link region' within RNAP β subunit and the 'bridge-helix N-terminal hinge' within RNAP β' subunit 8 ). Substitutions of the RNAP β subunit that confer high-level resistance to the structurally unrelated RNAP inhibitor rifampin do not confer resistance to salinamide F (Table 3) . We infer that salinamide F, like salinamides A and B, 8 does not interact with the rifampin binding site on RNAP.
